{"id":"NCT03732833","sponsor":"Medy-Tox","briefTitle":"MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines","officialTitle":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-05","primaryCompletion":"2020-03-05","completion":"2021-01-25","firstPosted":"2018-11-07","resultsPosted":"2023-07-17","lastUpdate":"2023-07-17"},"enrollment":425,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lateral Canthal Lines","Glabellar Lines"],"interventions":[{"type":"DRUG","name":"MT10109L","otherNames":["NivobotulinumtoxinA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MT10109L Dose 1 + Placebo","type":"EXPERIMENTAL"},{"label":"MT10109L Dose 1 + MT10109L Dose 2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.","primaryOutcome":{"measure":"The Percentage of Participants With a â‰¥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND PARTICIPANT Assessments of LCL Severity at Maximum Smile at Day 30","timeFrame":"Day 30","effectByArm":[{"arm":"Placebo","deltaMin":0,"sd":null},{"arm":"MT10109L 24U + Placebo","deltaMin":35,"sd":null},{"arm":"MT10109L 24U + MT10109L 20U","deltaMin":38,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":12},"locations":{"siteCount":20,"countries":["United States","Canada","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":86},"commonTop":["Injection site pain","Nasopharyngitis","Headache","Injection site haemorrhage","Upper respiratory tract infection"]}}